Latest News

Compass Pathways (NASDAQ:CMPS) executives said the company remains on track to target a fourth-quarter New Drug Application filing for COMP360, its synthetic psilocybin treatment candidate for treatment-resistant depression, while preparing commercially for a potentially accelerated regulatory timel

It all comes down to whether you trust management to deliver its long-term turnaround plan.

Climb Bio (NASDAQ:CLYM) outlined its clinical development strategy and upcoming data readouts during a fireside chat at H.C. Wainwright’s BioConnect Conference, with management emphasizing two biologic drug programs aimed at immune-mediated diseases, including nephrology and hematology indications.

Nvidia now sees sales growing an astounding 95% in the current quarter, and that's without any China sales.

Charter Communications (NASDAQ:CHTR) Chief Financial Officer Jessica Fischer said the company’s top priority remains growing its connectivity business while it works through major investment initiatives, prepares for the integration of Cox assets and seeks to improve free cash flow as capital spendi

Anthropic is reportedly nearing its first quarterly profit as revenue tops $10 billion amid booming demand for Claude AI.